Overview
Lentigo maligna melanoma (LMM) is a subtype of cutaneous melanoma. Management of cutaneous melanoma aims to homogenize treatment approaches for affected patients 1.Diagnosis
Histological confirmation is required for diagnosis 1.
BRAF status determination is recommended for patients with stage $\ge$ III melanoma 1.Management
Surgical treatment is indicated for stage I-III resectable melanomas 1.
Adjuvant treatment with immunotherapy or targeted therapy is recommended for patients with stage III melanoma 1.
For unresectable or metastatic melanoma, treatment with immunotherapy or targeted therapy is recommended 1.
The optimal sequence of immunotherapy or targeted therapy for unresectable or metastatic melanoma remains unclear 1.
Brain metastases require consideration for both systemic and local treatment 1.Key Recommendations
Histological diagnosis is mandatory for melanoma 1. (Evidence: Expert opinion)
BRAF status determination should be performed in patients with stage $\ge$ III melanoma 1. (Evidence: Expert opinion)
Surgical treatment is the standard for stage I-III resectable melanomas 1. (Evidence: Expert opinion)
Adjuvant immunotherapy or targeted therapy is recommended for stage III melanoma 1. (Evidence: Expert opinion)
Immunotherapy or targeted therapy is recommended for unresectable or metastatic melanoma 1. (Evidence: Expert opinion)References
1 Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E et al.. SEOM clinical guideline for the management of cutaneous melanoma (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021. link